This is what analysts have to say about Concordia International Corp. (TSE:CXR) after last week.

March 22, 2018 - By Stephen Andrade

 This is what analysts have to say about Concordia International Corp. (TSE:CXR) after last week.

Concordia International Corp. (TSE:CXR) Ratings Coverage

Among 4 analysts covering Concordia Healthcare Corp (TSE:CXR), 0 have Buy rating, 3 Sell and 1 Hold. Therefore 0 are positive. Concordia Healthcare Corp had 34 analyst reports since August 11, 2015 according to SRatingsIntel. The stock has “Outperform” rating by RBC Capital Markets on Monday, October 17. The stock of Concordia International Corp. (TSE:CXR) has “Outperform” rating given on Tuesday, October 11 by RBC Capital Markets. Scotia Capital maintained it with “Sector Outperform” rating and $100 target in Wednesday, September 9 report. The stock has “Hold” rating by Mackie on Thursday, December 3. The firm has “Outperform” rating given on Tuesday, August 11 by RBC Capital Markets. Scotia Capital maintained it with “Underperform” rating and $0.50 target in Thursday, March 16 report. The firm has “Outperform” rating by RBC Capital Markets given on Monday, October 24. The stock of Concordia International Corp. (TSE:CXR) earned “Outperform” rating by RBC Capital Markets on Friday, January 8. Goldman Sachs maintained Concordia International Corp. (TSE:CXR) rating on Friday, July 22. Goldman Sachs has “” rating and $34 target. The rating was maintained by RBC Capital Markets on Monday, November 28 with “Sector Perform”. Below is a list of Concordia International Corp. (TSE:CXR) latest ratings and price target changes.

The stock decreased 2.86% or $0.02 during the last trading session, reaching $0.68. About 5,075 shares traded. Concordia International Corp. (TSE:CXR) has 0.00% since March 22, 2017 and is . It has underperformed by 16.70% the S&P500.

Concordia International Corp., a specialty pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products. The company has market cap of $34.87 million. It operates through three divisions: Concordia International, Concordia North America, and Orphan Drugs. It currently has negative earnings. The Concordia International segment owns or licenses a portfolio of branded and generic prescription products to wholesalers, hospitals, and pharmacies.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: